Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.

about

Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.

Item

http://www.wikidata.org/entity/Q36644797

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@ast

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@en

type

Item

label

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@ast

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@en

prefLabel

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@ast

Immunogenicity of influenza H1 ...... effect of disease and therapy.

@en

P1476

Immunogenicity of influenza H1 ...... effect of disease and therapy

@en

P2093

Ana Cristina M Ribeiro

http://www.w3.org/2001/XMLSchema#string

Carla G S Saad

http://www.w3.org/2001/XMLSchema#string

M Teresa C Caleiro

http://www.w3.org/2001/XMLSchema#string

Maria A Ishida

http://www.w3.org/2001/XMLSchema#string

Renata Miossi

http://www.w3.org/2001/XMLSchema#string

Ricardo Fuller

http://www.w3.org/2001/XMLSchema#string

P2860

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.

Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.

Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.

Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.

Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?

Prognostic value of anti-dsDNA in SLE

Mixed connective tissue disease.

P304

129-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6061/CLINICS/2013(02)OA02

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23525305

http://www.w3.org/2001/XMLSchema#string

P921

connective tissue

P932

3584286

http://www.w3.org/2001/XMLSchema#string